LeadIQ logo
Learn more at LeadIQ.com

Insights

Clinical Trials Focus Humacyte is actively conducting late-stage clinical trials for its human acellular vessels with applications in vascular trauma repair, hemodialysis access, and peripheral arterial disease. This presents an opportunity to engage healthcare institutions looking for innovative solutions to improve patient outcomes.

Technology Adoption Humacyte utilizes a range of technology tools such as jsDelivr, Microsoft Word, and TweenMax in its biotechnology research. This tech-savvy approach can resonate with organizations seeking partners who leverage cutting-edge tech for advancements in the medical field.

Recent Funding With a recent financing round of $30 million, Humacyte has the financial backing to further develop its bioengineered human tissues platform. This financial stability signals a growth phase that could attract investors and collaborators looking to support pioneering biotech ventures.

Strategic Partnerships Humacyte's collaboration with Pluristyx for developing a BioVascular Pancreas using iPSCs showcases a focus on innovative treatments. This partnership creates opportunities for sales representatives to explore synergies with companies involved in regenerative medicine and stem cell technologies.

Regulatory Recognition Humacyte's FDA's RMAT expedited review designation for its human acellular vessels highlights regulatory recognition and validation of its products. Sales professionals can leverage this designation to build credibility with healthcare organizations prioritizing FDA-approved solutions for patient care.

Similar companies to Humacyte

Humacyte Tech Stack

Humacyte uses 8 technology products and services including jsDelivr, Microsoft Word, ADP Workforce Now, and more. Explore Humacyte's tech stack below.

  • jsDelivr
    Content Delivery Network
  • Microsoft Word
    Editors
  • ADP Workforce Now
    Human Capital Management
  • TweenMax
    Javascript Frameworks
  • jQuery UI
    Javascript Libraries
  • Buildout
    Real Estate Marketing
  • reCAPTCHA
    Security
  • Concur
    Travel And Expense Management

Media & News

Humacyte's Email Address Formats

Humacyte uses at least 1 format(s):
Humacyte Email FormatsExamplePercentage
FLast@humacyte.comJDoe@humacyte.com
53%
Last@humacyte.comDoe@humacyte.com
33%
First.Last@humacyte.comJohn.Doe@humacyte.com
12%
FirstLast@humacyte.comJohnDoe@humacyte.com
2%

Frequently Asked Questions

Where is Humacyte's headquarters located?

Minus sign iconPlus sign icon
Humacyte's main headquarters is located at 2525 E NC Highway 54 2525 E Hwy 54 Durham, NC 27713 US. The company has employees across 2 continents, including North AmericaEurope.

What is Humacyte's phone number?

Minus sign iconPlus sign icon
You can contact Humacyte's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Humacyte's stock symbol?

Minus sign iconPlus sign icon
Humacyte is a publicly traded company; the company's stock symbol is HUMA.

What is Humacyte's official website and social media links?

Minus sign iconPlus sign icon
Humacyte's official website is humacyte.com and has social profiles on LinkedIn.

How much revenue does Humacyte generate?

Minus sign iconPlus sign icon
As of October 2024, Humacyte's annual revenue reached $35M.

What is Humacyte's SIC code NAICS code?

Minus sign iconPlus sign icon
Humacyte's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Humacyte have currently?

Minus sign iconPlus sign icon
As of October 2024, Humacyte has approximately 218 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: H. M.Chief Commercial Officer: B. S.Chief Regulatory Officer: B. T.. Explore Humacyte's employee directory with LeadIQ.

What industry does Humacyte belong to?

Minus sign iconPlus sign icon
Humacyte operates in the Biotechnology Research industry.

What technology does Humacyte use?

Minus sign iconPlus sign icon
Humacyte's tech stack includes jsDelivrMicrosoft WordADP Workforce NowTweenMaxjQuery UIBuildoutreCAPTCHAConcur.

What is Humacyte's email format?

Minus sign iconPlus sign icon
Humacyte's email format typically follows the pattern of . Find more Humacyte email formats with LeadIQ.

How much funding has Humacyte raised to date?

Minus sign iconPlus sign icon
As of October 2024, Humacyte has raised $40M in funding. The last funding round occurred on Feb 29, 2024 for $40M.

When was Humacyte founded?

Minus sign iconPlus sign icon
Humacyte was founded in 2004.
Humacyte

Humacyte

Biotechnology ResearchNorth Carolina, United States201-500 Employees

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Section iconCompany Overview

Headquarters
2525 E NC Highway 54 2525 E Hwy 54 Durham, NC 27713 US
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
HUMA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
201-500

Section iconFunding & Financials

  • $40M

    Humacyte has raised a total of $40M of funding over 11 rounds. Their latest funding round was raised on Feb 29, 2024 in the amount of $40M.

  • $10M$50M

    Humacyte's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $40M

    Humacyte has raised a total of $40M of funding over 11 rounds. Their latest funding round was raised on Feb 29, 2024 in the amount of $40M.

  • $10M$50M

    Humacyte's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.